Connect with us

Published

on

Due to the imminent threat of climate change and expected legal measures, companies across different sectors are increasingly driven to set and actively pursue sustainability objectives.

The pharmaceutical sector, faced with rising stakeholder expectations and tightening regulations, is accelerating efforts to reduce its environmental impact. Several major players in the industry have committed to achieving net-zero emissions as their climate sustainability target. These leading pioneers are blazing the trail by implementing policies and undertaking initiatives, including the purchase of carbon credits, to accomplish this ambitious objective.

 

The pharmaceutical industry’s carbon footprint

The pharmaceutical sector is a significant contributor to global emissions. If it were a country, its carbon footprint would rank 9th in the world. Energy-intensive manufacturing processes, extensive distribution networks, and greenhouse gas-emitting propellants in inhalers drive up the industry’s climate impacts. Experts urge pharmaceutical companies to act, as unmitigated warming could strain global health systems and hinder access to vital medications.

While daunting, the mission is not impossible. Industries like tech and retail are demonstrating that reaching net-zero is within grasp. Google aims to run entirely on carbon-free energy by 2030. IKEA plans to become climate positive by 2030 by reducing more greenhouse gas emissions than its value chain emits. These commitments raise the bar for pharmaceutical companies to take equally bold climate action.

Major industry players are stepping up. AstraZeneca, Novartis, and Takeda have set ambitious net-zero targets, while investing in renewable energy, green chemistry innovation, and carbon removal. Their efforts are having ripple effects as peers follow suit. With collaboration and persistence, the pharmaceutical industry can curb its emissions in line with climate science.

 

AstraZeneca’s U$1BN of climate commitments

With over $26 billion in annual revenue, British-Swedish firm AstraZeneca is one of the world’s largest pharmaceutical companies. It manufactures blockbuster treatments ranging from diabetes to oncology medications.

In 2020, AstraZeneca announced its Ambition Zero Carbon strategy, aiming to achieve carbon neutrality across its entire value chain by 2030. This bold pledge puts AstraZeneca at the vanguard of climate action in pharma.

To meet its goal, AstraZeneca is transitioning to 100% renewable electricity at its sites by 2025. It is also optimizing manufacturing to curb emissions, while partnering with suppliers to reduce their carbon footprints. Further, AstraZeneca plans to eliminate fossil fuel vehicles from its fleet by 2030.

Beyond its operations, AstraZeneca is developing a portfolio of over $1 billion in green investments. These include carbon removal and storage solutions expected to offset about 2.5 million tonnes of CO2 annually by 2025.

AstraZeneca’s commitment is spurring the industry to accelerate sustainability initiatives. Being the pioneer in the pharmaceutical industry to establish a bold net-zero objective that encompasses its entire value chain, AstraZeneca is setting a remarkable example that its competitors will have to strive to emulate.

 

Novartis to use 100% renewable energy within 2023

Headquartered in Switzerland, Novartis is a leading global medicines company with over $48 billion in 2021 revenue. Its therapeutic areas span eye care, immunology, and cardiovascular treatments.

In 2021, Novartis announced its aim to achieve carbon neutrality across Scopes 1, 2, and 3 by 2040. Scope 1 and 2 cover direct emissions from Novartis’ operations, while Scope 3 includes indirect emissions across its supply chain.

Novartis’ environmental policies are publicly available on the internet. The company has made meeting its net-zero ambition a top priority, with a strong and focused approach in four crucial areas: sourcing renewable electricity, enhancing energy efficiency, promoting innovative green chemistry, and investing in carbon removal offsets.

Already, Novartis sources 80% of its electricity from renewables. It is also optimizing production processes, deploying automation, and modifying fleet vehicles to curb emissions. The company is on track to source 100% of its power from renewables by years’ end of 2023.

Additionally, Novartis is pioneering molecular design techniques to develop medicines with lower environmental impacts. Furthermore, the company is actively investing in projects that focus on nature-based carbon removal, such as collaborating with Carbon Direct to expand the implementation of carbon forestry offsets.

By setting and working toward net-zero science-based targets, Novartis is positioning itself as a leader in green pharmaceutical manufacturing. Its multipronged approach can serve as a model for other companies.

 

Takeda Pharmaceuticals shows the way for Asia

Japan’s largest pharmaceutical company, Takeda Pharmaceutical generates over $30 billion in annual revenue from medicines treating conditions from cancer to rare diseases.

In 2021, Takeda announced its commitment to achieving net-zero greenhouse gas emissions by 2040. It is working to reduce and offset its entire carbon footprint, including Scope 3 emissions from its supply chain.

Takeda is achieving its goal by increasing renewable electricity usage, improving energy efficiency at its sites, electrifying its vehicle fleet, and reducing emissions from business travel. It aims to cut Scopes 1 and 2 emissions 46% by 2030.

Takeda is also collaborating with pharmaceutical industry partners and suppliers to curb emissions across its value chain under the Pharmaceutical Supply Chain Initiative. And it plans to utilize carbon removal offsets for hard-to-abate emissions.

Takeda’s pledge to achieve net-zero marks a groundbreaking moment for the pharmaceutical industry in Asia and beyond, as they lead the charge towards comprehensive decarbonization. Its 2040 target and interim science-based milestones demonstrate meaningful leadership.

 

Pharma’s challenges in reaching net-zero

Despite strong commitments from sustainability front-runners, achieving net-zero emissions poses complex challenges for pharmaceutical companies. Many production processes inherently rely on fossil fuels as heat sources and for transporting materials. Companies need major capital investments to transition these operations to clean energy alternatives.

Pharmaceutical distribution and long, complex supply chains also make emissions reductions difficult. Cold chain storage and last-mile delivery result in substantial greenhouse gas outputs. Meanwhile, developing green chemistry solutions requires years of research and development, along with new manufacturing infrastructure. These costs can be prohibitive. Further, credibly offsetting all residual emissions will necessitate scaled up, verifiable carbon removal markets. Technical and economic hurdles remain for many offset types.

 

Overcoming Challenges

While obstacles exist, experts emphasize they can be solved through collaboration, innovation, and policy action.

Companies can join forces and share their knowledge and resources through initiatives like the Pharmaceutical Supply Chain Initiative. This collaboration enables them to not only expand their renewable energy procurement, but also boost their efficiency and make strides in green chemistry.

Governments can help by offering incentives for clean technology investments and funding research into pharmaceutical process improvements.

International cooperation can accelerate decarbonization of global supply chains. And standardized offset methodologies will ensure carbon removal credits have integrity.

Ultimately, reaching net-zero will depend on persistence, investment, and cross-industry partnership. But the health and environmental benefits make it imperative for pharmaceutical companies to see it through.

 

Opportunities from net-zero efforts

Pursuing net-zero also opens up opportunities for pharmaceutical companies to add business value, beyond environmental benefits. Optimizing processes for energy efficiency provides cost savings from reduced power consumption and heating needs. Streamlining supply chains also cuts costs over the long-term.

First movers on net-zero can boost their reputations with consumers and investors, who increasingly prioritize sustainability. These companies may have better talent recruitment and retention.

Developing and marketing lower carbon medicines can become a competitive advantage. Doctors and health systems are paying more attention to the climate footprint of drugs.

AstraZeneca’s partnerships have the potential to unlock opportunities for companies to venture into the burgeoning green investment markets. Through these collaborations, businesses can not only contribute to the sustainability of our planet but also reap financial benefits by investing in carbon removal and renewable energy projects.

Finally, building climate resilience helps ensure business continuity as physical impacts of climate change accelerate.

 

Government policy propels climate action

Governments are ramping up policies aimed at decarbonizing pharmaceutical value chains through incentives and requirements.

The Inflation Reduction Act of 2022 in the United States presents an extraordinary opportunity, providing over $60 billion in incentives dedicated to fostering energy efficiency, electrification, and groundbreaking advancements in green chemistry. This can offset costs for companies pursuing these strategies.

The EU’s pharmaceutical strategy aims to make drug manufacturing and distribution more sustainable by implementing green product design and procurement requirements. This will help reduce emissions.

India released a roadmap in 2022 pushing pharmaceutical companies to adopt renewable energy and assess Scope 3 climate impacts. It aims to help India meet its national climate targets.

Such policies encourage pharmaceutical companies to take ownership of their emissions and are likely to expand as more governments declare net-zero commitments.

 

The Road Ahead

While the 2030s and 2040s may seem like distant milestones, reaching net-zero requires immediate action across pharmaceutical supply chains. Industry leaders have provided a blueprint – including renewable energy procurement, distribution optimization, green chemistry, and carbon removal.

New technologies and nature-based solutions are expanding decarbonization opportunities. With collective willpower, strategic investment, and transparent reporting, net-zero is within the pharmaceutical industry’s reach. All stakeholders must maintain pressure and hold firms accountable to their pledges for a sustainable future.

 

Photo credit

Photo by Myriam Zilles on Unsplash

Carbon Footprint

Why a forest with more species stores more carbon

Published

on

A forest is not just trees. The number of species it holds, from canopy giants to understorey shrubs to soil fungi, directly determines how much carbon it can absorb, and, more importantly, how much it can keep over time. Buyers of carbon credits increasingly ask a reasonable question: Is the carbon in this project long-lasting? The science of biodiversity has a clear answer.

Continue Reading

Carbon Footprint

OpenAI Hits Pause on $40B UK AI Project: Energy Costs Shake Data Center Economics

Published

on

OpenAI Hits Pause on $40B UK AI Project: Energy Costs Shake Data Center Economics

ChatGPT developer OpenAI has paused its flagship UK data center project, known as “Stargate UK,” citing high energy costs and regulatory uncertainty. The project was part of a broader £31 billion ($40+ billion) investment plan aimed at expanding artificial intelligence (AI) infrastructure in the country.

The initiative was designed to deploy up to 8,000 GPUs initially, with plans to scale to 31,000 GPUs over time. It was aimed to boost the UK’s “sovereign compute” capacity. This means building local infrastructure to support AI development and reduce reliance on foreign systems.

However, the company has now paused development. An OpenAI spokesperson stated that they:

“…support the government’s ambition to be an AI leader. AI compute is foundational to that goal – we continue to explore Stargate UK and will move forward when the right conditions such as regulation and the cost of energy enable long-term infrastructure investment.”

Energy Costs Are Now a Core Constraint

The main issue is energy. AI data centers require large amounts of electricity to run GPUs and cooling systems.

In the UK, industrial electricity prices are among the highest in developed markets. Recent estimates show costs at around £168 per megawatt-hour, compared to £69 in France and £38 in Texas. This gap creates a major disadvantage for large-scale data center investments.

AI workloads are especially power-intensive. A single large data center can consume as much electricity as tens of thousands of homes. As AI adoption grows, this demand is rising quickly.

Globally, the International Energy Agency estimates that data centers could consume over 1,000 terawatt-hours (TWh) of electricity by 2030, up sharply from about 415 TWh in 2024. This growth is largely driven by AI. 

data center electricity use 2035
Source: IEA

The result is clear. Energy is no longer just a cost. It is a key factor in where AI infrastructure gets built.

Regulation Adds Another Layer of Risk

Energy is only part of the challenge. Regulation is also slowing investment. In the UK, uncertainty around AI rules, especially copyright laws for training data, has created hesitation among companies.

Earlier proposals to allow AI firms to use copyrighted content were withdrawn after backlash. This left companies without clear guidance on compliance.

For large infrastructure projects, this uncertainty increases risk. Data centers require billions in upfront investment. Companies need stable rules before committing capital.

Planning delays and grid connection timelines also add friction. These factors increase both cost and project timelines.

Together, energy costs and regulatory uncertainty create a difficult environment for hyperscale AI infrastructure.

OpenAI’s Global Infrastructure Expands, But More Selectively

Despite the pause, ChatGPT-maker is still expanding globally. The company is investing heavily in AI infrastructure through partnerships with Microsoft, NVIDIA, and Oracle. It is also linked to a much larger $500 billion “Stargate” initiative in the United States, focused on building next-generation AI data centers.

At the same time, the company faces rising costs. Reports suggest OpenAI could lose billions of dollars annually as it scales infrastructure to meet demand.

This reflects a broader industry shift. AI is becoming more like energy or telecom infrastructure. It requires large capital investment, long timelines, and stable operating conditions.

The pause also highlights a deeper issue. AI growth is increasing pressure on energy systems and the environment.

The Hidden Carbon Cost Behind Every AI Query

ChatGPT and similar tools rely on large data centers. These facilities already account for about 1% to 1.5% of global electricity use. Projections for their energy use vary widely due to various factors. 

Each individual query may seem small. A typical ChatGPT request can use about 0.3 watt-hours of electricity, which is relatively low. However, usage at scale changes the picture.

ChatGPT now serves hundreds of millions of users. Even small energy use per query adds up quickly. Training models is even more energy-intensive. For example, training GPT-3 required about 1,287 megawatt-hours of electricity and produced roughly 550 metric tons of CO₂.

chatgpt environmental footprint

Newer models are even larger. Some estimates suggest training advanced models like GPT-4 could emit up to 15,000 metric tons of CO₂, depending on the energy source.

At the system level, the impact is growing fast. AI systems could generate between 32.6 and 79.7 million tons of CO₂ emissions in 2025 alone. By 2030, AI-driven data centers could add 24 to 44 million tons of CO₂ annually.

AI servers annual carbon emissions
Note: carbon emissions (g) of AI servers from 2024 to 2030 under different scenarios. The red dashed lines in e–g denote the forecast footprint of the US data centres, based on previous literature. Source: https://doi.org/10.1038/s41893-025-01681-y

Looking further ahead, global generative AI emissions could reach up to 245 million tons per year by 2035 if growth continues. These numbers show a clear pattern. Efficiency is improving, but total demand is rising faster.

Big Tech Scrambles to Balance AI Growth and Emissions

OpenAI has not published a detailed standalone net-zero target. However, its operations rely heavily on partners such as Microsoft, which has committed to becoming carbon negative by 2030.

The company has acknowledged that energy use is a real concern. Leadership has pointed to the need for more renewable energy, including nuclear and clean power, to support AI growth.

Across the industry, companies are responding in several ways:

  • Improving model efficiency to reduce energy per query
  • Investing in renewable energy and long-term power contracts
  • Exploring new cooling systems to reduce water and energy use

Efficiency gains are already visible. Some AI systems have reduced energy per query by more than 30 times within a year, showing how quickly technology can improve. Still, total emissions continue to rise because demand is scaling faster than efficiency gains.

The Global AI Infrastructure Race

The pause in the UK highlights a larger trend. AI infrastructure is becoming a global competition shaped by energy, policy, and cost.

Regions with lower energy prices and faster permitting processes have an advantage. The United States and parts of the Middle East are attracting large-scale AI investments due to cheaper power and supportive policies.

At the same time, governments are trying to attract these projects. The UK has pledged billions to support AI growth and improve compute capacity. But this case shows that policy ambition alone is not enough. Companies need reliable energy, clear rules, and predictable costs.

AI’s Next Phase Will Be Decided by Energy, Not Code

The decision by OpenAI does not signal a retreat from AI investment. Instead, it reflects a shift in priorities.

Companies are becoming more selective about where they build infrastructure. They are focusing on locations that offer the right mix of energy access, cost stability, and regulatory clarity.

The UK project may still move forward, but only if conditions improve. For now, the message is clear. The future of AI will not be shaped by technology alone. It will also depend on energy systems, policy frameworks, and long-term investment conditions.

The post OpenAI Hits Pause on $40B UK AI Project: Energy Costs Shake Data Center Economics appeared first on Carbon Credits.

Continue Reading

Carbon Footprint

U.S. Uranium Mining Returns: UEC Launches First New Mine in a Decade

Published

on

U.S. Uranium Mining Returns: UEC Launches First New Mine in a Decade

Uranium Energy Corporation (NYSE: UEC) has started production at its Burke Hollow project in South Texas. This is the first new uranium mine to open in the U.S. in over ten years.

The project started production in April 2026 after getting final regulatory approval. This marks a big step for domestic uranium supply. It’s also the world’s newest in-situ recovery (ISR) uranium mine, which shows a move toward less harmful extraction methods.

Burke Hollow was originally discovered in 2012 and spans roughly 20,000 acres, with only about half of the site explored so far. This suggests significant long-term expansion potential as additional wellfields are developed.

The mine’s output will go to UEC’s Hobson Central Processing Plant in Texas. This plant can produce up to 4 million pounds of uranium each year.

A Scalable ISR Platform Expands U.S. Uranium Capacity

The Burke Hollow launch transforms UEC into a multi-site uranium producer in the United States. The company runs two active ISR production platforms. The second one is at its Christensen Ranch facility in Wyoming; both are shown in the table from UEC.

UEC burke hollow resources

UEC Christensen Ranch resources

This “hub-and-spoke” model allows uranium from multiple wellfields to be processed through centralized facilities, improving efficiency and scalability. UEC’s operations in Texas and Wyoming are now active. This gives them a licensed production capacity of about 12 million pounds per year across the U.S.

ISR mining plays a key role in this strategy. Unlike conventional mining, ISR involves circulating solutions underground to dissolve uranium and pump it to the surface. This reduces surface disturbance and can lower environmental impact compared to open-pit or underground mining.

Burke Hollow is the largest ISR uranium discovery in the U.S. in the last ten years. This boosts its long-term value as a domestic resource.

Unhedged Strategy Pays Off as Uranium Prices Rise

UEC’s production launch comes at a time of strong uranium market conditions. The company uses a fully unhedged strategy. This means it sells uranium at current market prices instead of securing long-term contracts.

This approach has recently delivered strong financial results. In early 2026, UEC sold 200,000 pounds of uranium for $101 each. This price was about 25% higher than average market rates. The sale brought in over $20 million in revenue and around $10 million in gross profit.

The strategy allows the company to benefit directly from rising uranium prices, which have been supported by:

  • Growing global nuclear energy demand
  • Supply constraints in key producing regions
  • Increased long-term contracting by utilities

Unhedged exposure raises risk in downturns, but offers more upside in strong markets. UEC is currently taking advantage of this.

Nuclear Energy Growth Is Driving Demand for Uranium

The timing of Burke Hollow’s launch aligns with a broader global shift back toward nuclear energy. Governments are increasingly turning to nuclear power as a reliable, low-carbon energy source.

nuclear power capacity additions IAEA projection 2024 to 2050
Source: IAEA

The International Atomic Energy Agency projects that global nuclear capacity could double by 2050, depending on policy and investment trends. This would require a significant increase in uranium supply.

In the United States, nuclear energy accounts for around 20% of electricity generation. It also produces zero carbon emissions during operations. This makes it a key component of many net-zero strategies.

There are several factors supporting renewed nuclear demand, including:

  • Development of small modular reactors (SMRs)
  • Extension of existing nuclear plant lifetimes
  • Government funding to maintain nuclear capacity
  • Rising electricity demand from data centers and electrification

As demand grows, securing a reliable uranium supply becomes increasingly important.

uranium demand and supply UEC

Reducing Import Risk: A Strategic Domestic Supply Push

The Burke Hollow project also addresses a major vulnerability in U.S. energy policy. The country currently imports about 95% of its uranium needs, leaving it exposed to global supply risks.

A large share of uranium production and enrichment capacity is concentrated in a few countries, including Russia and Kazakhstan. This concentration has raised concerns about supply disruptions and geopolitical risk.

uranium production US 2025 EIA

By expanding domestic production, UEC is helping to reduce reliance on imports and strengthen the U.S. nuclear fuel supply chain.

The company’s broader strategy includes building a vertically integrated platform covering mining, processing, and, eventually, uranium conversion. This approach aligns with U.S. government efforts to rebuild domestic nuclear fuel capabilities.

Federal programs have allocated billions to boost uranium production and enrichment. This shows how important the sector is.

Two Hubs, One Strategy: Wyoming Supports the Texas Breakthrough

While Burke Hollow is the main focus, UEC’s Christensen Ranch operation in Wyoming remains an important part of its production base.

The Wyoming site has recently received approvals for expanded wellfield development, allowing it to increase output alongside the Texas operation.

Together, the two sites form the foundation of UEC’s dual-hub production model. However, it is the Texas project that marks the first new U.S. uranium mine in over a decade, making it the central milestone in the company’s growth strategy.

Investor Momentum Builds Around Uranium Revival

The restart of U.S. uranium production is drawing strong attention from investors and industry players. Uranium markets have tightened in recent years, driven by rising demand and limited new supply.

UEC’s production launch has already had a positive market impact. The company’s share price rose following the announcement, reflecting investor confidence in its growth strategy.

UEC stock price

At the same time, utilities are increasing long-term contracting activity to secure fuel supply. This trend is expected to continue as new nuclear capacity comes online and existing plants extend operations.

Industry forecasts suggest that uranium demand will remain strong through the 2030s, supporting higher prices and increased investment in new production.

Lower Impact Mining, Higher ESG Expectations

The use of ISR mining at Burke Hollow reflects a broader shift toward more sustainable extraction methods. ISR typically reduces land disturbance and avoids large-scale excavation.

However, environmental management remains critical. Key issues include groundwater protection, chemical use, and long-term site restoration.

UEC has emphasized environmental controls and regulatory compliance in its operations. These efforts are important for maintaining social license and meeting ESG expectations.

From a climate perspective, uranium production plays an indirect but important role. Supporting nuclear energy, it helps enable low-carbon electricity generation and reduces reliance on fossil fuels.

The Bottom Line: A Defining Moment for U.S. Uranium Production

The launch of the Burke Hollow mine marks a major milestone for the U.S. uranium sector. It ends a decade-long gap in new mine development and signals renewed momentum in domestic production.

In the short term, it strengthens supply and supports rising uranium markets. In the long term, it highlights the growing role of nuclear energy in global decarbonization strategies.

UEC’s Burke Hollow shows that new uranium projects can advance in today’s market. There are still challenges, like scaling production and handling environmental risks, but progress is possible.

As demand for nuclear energy continues to grow, domestic projects like Burke Hollow will play a key role in shaping the future of energy security and low-carbon power.

The post U.S. Uranium Mining Returns: UEC Launches First New Mine in a Decade appeared first on Carbon Credits.

Continue Reading

Trending

Copyright © 2022 BreakingClimateChange.com